Page last updated: 2024-12-04

homovanillic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Homovanillic acid (HVA) is a major metabolite of dopamine, a neurotransmitter that plays a crucial role in mood, motivation, and movement. It is produced in the brain by the breakdown of dopamine and is then released into the bloodstream. HVA is measured in urine or blood samples to assess dopamine levels in the brain. Increased HVA levels are associated with certain medical conditions, such as pheochromocytoma, neuroblastoma, and carcinoid tumors. HVA is also a potential biomarker for Parkinson's disease, as its levels decrease in the cerebrospinal fluid of individuals with this disorder. Researchers study HVA to understand the role of dopamine in various physiological processes, such as mood regulation, reward pathways, and motor control. HVA is also being investigated as a potential therapeutic target for various neurological disorders. '

Homovanillic Acid: A 3-O-methyl ETHER of (3,4-dihydroxyphenyl)acetic acid. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

homovanillate : A hydroxy monocarboxylic acid anion which is obtained by deprotonation of the carboxy group of homovanillic acid. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

homovanillic acid : A monocarboxylic acid that is the 3-O-methyl ether of (3,4-dihydroxyphenyl)acetic acid. It is a catecholamine metabolite. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID1738
CHEMBL ID1562
CHEBI ID545959
SCHEMBL ID8792
MeSH IDM0010524

Synonyms (114)

Synonym
AKOS005447065
EU-0100632
homovanillic acid, fluorimetric reagent
LOPAC0_000632
acetic acid, (4-hydroxy-3-methoxyphenyl)-
(4-hydroxy-3-methoxyphenyl)acetic acid
vanillacetic acid
HVA ,
nsc16682
benzeneacetic acid, 4-hydroxy-3-methoxy-
4-hydroxy-3-methoxyphenylacetic acid
4-hydroxy-3-methoxybenzeneacetic acid
nsc-16682
3-methoxy-4-hydroxyphenylacetic acid
lopac-h-1252
NCGC00015497-01
OPREA1_505423
STK372679
C05582
3-methoxy-4-hydroxyphenylacetate
homovanillate
306-08-1
homovanillic acid
MLS001056771
NCGC00093999-03
smr000326729
NCGC00093999-01
NCGC00093999-02
H-3200
NCGC00015497-02
562F45C3-F314-46F6-8FC2-74D84EBB9CBC
H 1252
homovanillic acid; hva
CHEBI:545959 ,
NCGC00015497-05
inchi=1/c9h10o4/c1-13-8-4-6(5-9(11)12)2-3-7(8)10/h2-4,10h,5h2,1h3,(h,11,12)
qrmzspfsdqblix-uhfffaoysa-
3 methoxy 4 hydroxyphenylacetic acid
acid, 3-methoxy-4-hydroxyphenylacetic
4 hydroxy 3 methoxyphenylacetic acid
acid, 4-hydroxy-3-methoxyphenylacetic
acid, homovanillic
acetic acid, (4-hydroxy-3-methoxyphenyl)- (8ci)
BMSE000132
CHEMBL1562
H0339
2-(4-hydroxy-3-methoxyphenyl)acetic acid
HMS3261P06
unii-x77s6gms36
nsc 16682
x77s6gms36 ,
einecs 206-176-7
homovaniuic acid
homovanillinic acid
CCG-204720
HMS2233B24
NCGC00015497-03
NCGC00015497-04
FT-0627086
PS-3625
LP00632
S5642
SCHEMBL8792
homovanillic acid [mi]
4-hydroxy-3-methoxy-.alpha.-toluic acid
vanilacetic acid
hmdb00118
2-(4-hydroxy-3-methoxy-phenyl)acetic acid
tox21_500632
NCGC00261317-01
4-hydroxy-3-methoxy-phenylacetic acid
(4-hydroxy-3-methoxy-phenyl)-acetic acid
(4-hydroxy-3-methyoxy-phenyl)-acetic acid
4-hydroxy-3-methoxyphenyl-acetic acid
4-hydroxy-3-methoxyphenyacetic acid
53587-33-0
DTXSID5059791 ,
homovanilic acid
J-610010
STR09131
homovanillic-acid
mfcd00004350
4-hydroxy-3-methoxyphenylacetic-2,2-d2 acid
homovanillic acid, analytical standard
ytx ,
2-(3-methoxy-4-oxidanyl-phenyl)ethanoic acid
homovanillic acid, 98%
sr-01000075364
SR-01000075364-1
4-hydroxy-3-methoxybenzeneacetate
4-hydroxy 3-methoxyphenylacetic acid
vanilacetate
homovanilate
3-methoxy-4-hydroxy-phenylacetic acid
HY-N0384
CS-0008924
FT-0669241
HB1902
FT-0669240
Q903566
AMY18047
BBL100126
SDCCGSBI-0050613.P002
BCP33265
4-hydroxy-3-methoxyphenylacetic acid;vanillacetic acid;2-(4-hydroxy-3-methoxyphenyl)acetic acid
HMS3886C14
4-hydroxy-3-methoxy-benzeneacetic acid
NCGC00015497-08
4-hydroxy-3-methoxyphenylacetic acid homovanillic acid
EN300-179380
SY017698
4-hydroxy-3-methoxy-alpha-toluic acid
dtxcid4038219
Z1203162033

Research Excerpts

Overview

Homovanillic acid (HVA) is a metabolite of dopamine, reflecting central dopamine metabolism, primarily situated in the striatum. High proportion of patients with neuroblastoma excrete increased amounts of it in their urine.

ExcerptReferenceRelevance
"Homovanillic acid (HVA) is a major catabolite of dopamine. "( Biochemical diagnosis of dopaminergic disturbances in paediatric patients: analysis of cerebrospinal fluid homovanillic acid and other biogenic amines.
Artuch, R; Campistol, J; García-Cazorla, A; Marín-Valencia, I; Ormazabal, A; Pérez-Dueñas, B; Serrano, M, 2008
)
2
"Homovanillic acid was found to be a suitable fluorogen in the presence of 300 microM thiols from either dithiothreitol or reduced ribonuclease A."( A continuous fluorescence assay for sulfhydryl oxidase.
Glynn, NM; Raje, S; Thorpe, C, 2002
)
1.04
"Homovanillic acid (HVA) is a metabolite of dopamine, reflecting central dopamine metabolism, primarily situated in the striatum. "( Decreased homovanillic acid concentrations in cerebrospinal fluid in children without a known defect in dopamine metabolism.
Rotteveel, JJ; Van Der Heyden, JC; Wevers, RA, 2003
)
2.16
"Homovanillic acid is an important metabolite of dopamine, and a high proportion of patients with neuroblastoma excrete increased amounts of it in their urine. "( Improved colorimetry of urinary 3-methoxy-4-hydroxyphenylacetic acid (homovanillic acid).
Haymond, RE; Knight, JA, 1977
)
1.93
"Homovanillic acid is a weak organic acid, and its excretion probably resembles that of other organic acids (eg, p-aminohippuric acid) that are actively secreted by the kidney."( Effects of renal clearance on plasma concentrations of homovanillic acid. Methodologic cautions.
Goldman, SM; Hsiao, JK; Potter, WZ, 1989
)
1.25
"Homovanillic acid was shown to be a participant in a reaction with arachidonic acid/O2 stoichiometric ratios and is oxidized to a readily fluorescing product with an absorbance maximum (excitation) at 315 nm and fluorescence maximum at 425 nm."( [Prostaglandin H synthetase as a multisubstrate enzyme. Fluorimetric study of enzyme kinetics].
Kuznetsov, DA; Mevkh, AT; Sud'ina, GF; Varfolomeev, SD, 1986
)
0.99

Toxicity

ExcerptReferenceRelevance
" The results support the hypothesis of a positive correlation between the CSF HVA and the hypokinetic-rigid side effect and a negative correlation between the pretherapeutic dopamine turnover and the risk of neuroleptic Parkinsonism."( Hypokinetic-rigid extrapyramidal side effects of neuroleptics: the relationship of the silent period in EMG and HVA and 5-HIAA in CSF.
Baslo, A; Eroğlu, L; Hizal, A; Yazici, J; Yazici, O, 1986
)
0.27
" The 2,2 and 3,3-dimethyl analogs of 1-methyl-4-phenyl-2,3-dihydropyridinium cation which also cannot be oxidized to pyridinium species, reduced striatal dopamine, suggesting that these compounds are toxic in their own right."( On the mechanisms underlying 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity: the effect of perinigral infusion of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, its metabolite and their analogs in the rat.
Arora, PK; Blue, P; Harik, SI; Iacofano, LA; Sayre, LM; Schmidley, JW, 1987
)
0.27
" It is proposed that the retinal dopaminergic system is less sensitive to the toxic effects of MPTP than the nigro-striatal pathway."( Different sensitivities to MPTP toxicity in primate nigrostriatal and retinal dopaminergic systems: electrophysiological and biochemical evidence.
Di Paolo, T; Harnois, C; Marcotte, G, 1989
)
0.28
" MPP+ was found to be 2-3 orders of magnitude more toxic than the other two agents, consistent with the view that it is primarily responsible for MPTP neurotoxicity."( Comparative toxicity of MPTP, MPP+ and 3,3-dimethyl-MPDP+ to dopaminergic neurons of the rat substantia nigra.
Arora, PK; Harik, SI; Iacofano, LA; Sayre, LM, 1986
)
0.27
" The toxic dose of MA (5 mg/kg, sc, x4) significantly decreased contents of dopamine (DA), dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA) in the striatum (ST), and significantly decreased contents of serotonin (5-HT) in the ST, nucleus accumbens (NA) and medial frontal contex (MFC)."( Effects of nitric oxide synthesis inhibition on methamphetamine-induced dopaminergic and serotonergic neurotoxicity in the rat brain.
Abekawa, T; Koyama, T; Ohmori, T, 1996
)
0.5
" Together with the results of the N(G)-monomethyl-L-arginine and N(G)-nitro-L-arginine experiments, the data suggest that NO plays little or no role in the toxic mechanism of action of METH or MDMA."( Nitric oxide and the neurotoxic effects of methamphetamine and 3,4-methylenedioxymethamphetamine.
Finnegan, KT; Taraska, T, 1997
)
0.3
" L-DOPA pretreatment did not significantly alter any of the toxic effects of the amphetamine."( Neurotoxic effects of amphetamine plus L-DOPA.
Halladay, AK; Myers, CS; Wagner, GC; Widmer, DA, 1999
)
0.3
" Our findings suggest that the toxic effects of MPP+ on dopaminergic terminals are not mediated through a direct interaction with the NMDA subtype of glutamate receptor, but with the AMPA-kainate subtype."( The non-NMDA glutamate receptor antagonists 6-cyano-7-nitroquinoxaline-2,3-dione and 2,3-dihydroxy-6-nitro-7-sulfamoylbenzo(f)quinoxaline, but not NMDA antagonists, block the intrastriatal neurotoxic effect of MPP+.
Cano, J; Machado, A; Merino, M; Vizuete, ML, 1999
)
0.3
"The psychostimulant methamphetamine (MA) is toxic to nigro-striatal dopaminergic terminals in both experimental animals and humans."( Alpha-1B adrenergic receptor knockout mice are protected against methamphetamine toxicity.
Battaglia, G; Busceti, CL; De Blasi, A; Fornai, F; Lembo, G; Nicoletti, F, 2003
)
0.32
" All of these effects of ATR were observed at levels that were not toxic to the tissue, as LDH release into the medium (lactate dehydrogenase, an index of non-specific cytotoxicity) was not affected by ATR."( Dopaminergic toxicity of the herbicide atrazine in rat striatal slices.
Carr, RL; Filipov, NM; Sistrunk, SC; Stewart, MA, 2007
)
0.34
"Polychlorinated biphenyls (PCBs) are persistent environmental contaminants that are highly toxic to the developing nervous system, particularly via their disruption of dopamine (DA) function."( Polychlorinated biphenyl-induced neurotoxicity in organotypic cocultures of developing rat ventral mesencephalon and striatum.
Lyng, GD; Seegal, RF; Snyder-Keller, A, 2007
)
0.34
"The available scientific data indicate that the pathomechanism of Parkinson's disease (PD) involves the accumulation of endogenous and exogenous toxic substances."( Assessment of the role of multidrug resistance-associated proteins in MPTP neurotoxicity in mice.
Klivényi, P; Plangár, I; Szalárdy, L; Vécsei, L; Zádori, D, 2013
)
0.39
" The explanation of these findings would be that the stimulation of MRP1- and MRP2-mediated transport of glutathione conjugates of toxic substances may have slight beneficial effects, while stimulation of MRP4-mediated efflux of brain urate, which has an important antioxidant potency, may worsen the effects of oxidative stress."( Assessment of the role of multidrug resistance-associated proteins in MPTP neurotoxicity in mice.
Klivényi, P; Plangár, I; Szalárdy, L; Vécsei, L; Zádori, D, 2013
)
0.39
"Layered hydroxide nanoparticles are generally biocompatible, and less toxic than most inorganic nanoparticles, making them an acceptable alternative drug delivery system."( Toxicity and metabolism of layered double hydroxide intercalated with levodopa in a Parkinson's disease model.
Ain, NM; Fakurazi, S; Hussein, MZ; Hussein-Al-Ali, SH; Kura, AU, 2014
)
0.4

Pharmacokinetics

Plasma concentrations of levodopa; its metabolites 3-O-methyldopa (3-OMD), 3,4-dihydroxyphenylacetic acid (DOPAC), and homovanillic acid (HVA); as well as carbidopa and entacapone were determined for pharmacokinetic calculations. Pharmacokinetic data suggest that in man SIM2055 is promptly absorbed, quickly hydrolysed to epinine, metabolized to homovanillsic acid and conjugated with sulphuric acid.

ExcerptReferenceRelevance
"A series of studies on the pharmacokinetic and pharmacodynamic properties of some tricyclic antidepressants is reviewed."( Treatment of depression with tricyclic drugs--pharmacokinetic and pharmacodynamic aspects.
Asberg, M, 1976
)
0.26
" This review summarises that available pharmacokinetic data involving levodopa, especially as it relates to therapeutic response of parkinsonian patients."( Clinical pharmacokinetics of levodopa in parkinson's disease.
Bianchine, JR; Shaw, GM, 1976
)
0.26
"The possibility of a pharmacokinetic interaction between isosorbide-5-mononitrate (5-ISMN) and epinine, the active metabolite of ibopamine, has been investigated in 8 healthy male subjects given single doses of 200 mg ibopamine and 20 mg 5-ISMN, separately and together."( Investigation of a possible pharmacokinetic interaction between ibopamine and isosorbide-5-mononitrate.
De Sutter, J; De Wilde, G; Duprez, D; Lefebvre, RA; Pocchiari, F; Rosseel, MT, 1992
)
0.28
" administration of L-dopa, but had no effect on the half-life (t1/2) for its distribution or elimination."( Peripheral pharmacokinetic handling and metabolism of L-dopa in the rat: the effect of route of administration and carbidopa pretreatment.
Jenner, P; Marsden, CD; Rose, S, 1991
)
0.28
" Such pharmacokinetic behavior appeared to be related to the contractive effect of morphine on the bile duct, and naloxone facilitated the excretion of morphine via this route."( Naloxone affects both pharmacokinetics and pharmacodynamics of morphine. Application of direct correlation analysis.
Ishikawa, K; Kogure, M; Kubo, T; Shibanoki, S, 1991
)
0.28
" A pharmacodynamic model was set up to quantitatively describe the time-dependent adaptation of HVA accumulation in the whole rat brain during constant haloperidol administration."( A pharmacodynamic model to predict the time dependent adaptation of dopaminergic activity during constant concentrations of haloperidol.
Cheng, YF; Paalzow, LK, 1990
)
0.28
" The plasma RHAL:HAL ratios on days 6 and 7 were higher than and positively correlated with those at Tmax after a single dose of HAL and were negatively correlated with the HAL:RHAL ratios at Tmax after a single dose of RHAL."( Pharmacodynamics and pharmacokinetics of haloperidol and reduced haloperidol in schizophrenic patients.
Chang, WH; Chen, CT; Chen, TY; Hu, WH; Jann, MW; Lam, YW; Lin, SK; Yeh, EK, 1989
)
0.28
" The dopamine concentration in the striatum increased immediately after L-dopa injection, with the peak concentration (15."( Pharmacokinetic and pharmacodynamic studies of L-dopa in rats. II. Effect of L-dopa on dopamine and dopamine metabolite concentration in rat striatum.
Koitabashi, T; Koshiro, A; Sato, S, 1994
)
0.29
" Pharmacokinetic data suggest that in man SIM2055 is promptly absorbed, quickly hydrolysed to epinine, metabolized to homovanillic acid and 3,4-dihydroxy-phenylacetic acid, conjugated with sulphuric acid and excreted in large amounts into urine."( Kinetics and pharmacodynamic effects of a novel prodrug of N-methyldopamine at single dose in healthy volunteers.
De Caro, L; Ghizzi, A; Zunino, MT, 1993
)
0.49
" Plasma concentrations of levodopa; its metabolites 3-O-methyldopa (3-OMD), 3,4-dihydroxyphenylacetic acid (DOPAC), and homovanillic acid (HVA); as well as carbidopa and entacapone were determined for pharmacokinetic calculations."( The effect of catechol-O-methyl transferase inhibition by entacapone on the pharmacokinetics and metabolism of levodopa in healthy volunteers.
Gordin, A; Harjola, VP; Karlsson, M; Keränen, T; Korpela, K; Pentikäinen, PJ; Rita, H; Seppälä, L; Wikberg, T, 1993
)
0.49
" Plasma levodopa and levodopa metabolite pharmacokinetic profiles were determined using standard techniques."( A clinical and pharmacokinetic case study of an interaction of levodopa and antituberculous therapy in Parkinson's disease.
O'Connell, MT; Patsalos, PN; Quinn, NP; Wenning, GK, 1995
)
0.29
" Entacapone increased statistically significantly the mean area under the plasma concentration-time curve (AUC) of levodopa by 29% after a single dose and by 21% after 4 weeks' administration, without affecting other pharmacokinetic parameters of levodopa."( Effect of one month's treatment with peripherally acting catechol-O-methyltransferase inhibitor, entacapone, on pharmacokinetics and motor response to levodopa in advanced parkinsonian patients.
Rinne, UK; Ruottinen, HM, 1996
)
0.29
" A moment analysis was also made to obtain pharmacokinetic parameters."( In vivo microdialysis to determine the relative pharmacokinetics of drugs.
Ichikawa, M; Matsuyama, K; Nakashima, M; Nakashima, MN; Sakurai, M; Sasaki, H; Zhao, MF, 1996
)
0.29
" A temporal variation of the kinetics of both L-dopa and carbidopa was demonstrated with higher plasma clearance and lower area under concentration curve after the administration at 2200 hours."( Circadian phase dependent pharmacokinetics of L-dopa, its main metabolites (3-OMD, HVA, DOPAC) and carbidopa in rats.
Andre, MH; Bruguerolle, B; Grignon, S, 1996
)
0.29
"The objectives of this study were to assess potential pharmacokinetic and pharmacodynamic interactions between moclobemide and selegiline."( Pharmacokinetic-pharmacodynamic interactions between two selective monoamine oxidase inhibitors: moclobemide and selegiline.
Dingemanse, J; Kettler, R; Kneer, J; Korn, A; Koulu, M; Wallnöfer, A; Zürcher, G, 1996
)
0.29
" The period of escalating doses (EDs) is likely associated with development of tolerance to aspects of METH's pharmacologic and toxic effects but the relative contributions of pharmacokinetic and pharmacodynamic factors have not been well defined."( Escalating dose pretreatment induces pharmacodynamic and not pharmacokinetic tolerance to a subsequent high-dose methamphetamine binge.
Cho, AK; Kuczenski, R; Lacan, G; Melega, WP; O'Neil, ML; Segal, DS, 2006
)
0.33
"3% of the administered dose was taken up by the brain and was slowly eliminated, with a half-life of approximately 3 weeks."( Pharmacokinetic, neurochemical, stereological and neuropathological studies on the potential effects of paraquat in the substantia nigra pars compacta and striatum of male C57BL/6J mice.
Beck, M; Botham, PA; Breckenridge, CB; Butt, M; Cook, AR; Mathews, JM; Minnema, D; Smith, LL; Sturgess, NC; Tisdel, MO; Travis, KZ; Wolf, JC; Zadory, D, 2013
)
0.39
" Using nonlinear modeling, standard pharmacokinetic parameters were derived."( Fluoxetine: juvenile pharmacokinetics in a nonhuman primate model.
Golub, MS; Hogrefe, CE, 2014
)
0.4
" The objective of this study was to develop a population pharmacokinetic model for PDA and HVA to support biomarker qualification."( Population pharmacokinetic modeling and simulation to support qualification of pyridoxic acid as endogenous biomarker of OAT1/3 renal transporters.
Ahmad, A; Galetin, A; Jacobs, F; Kunze, A; Ogungbenro, K; Rostami-Hodjegan, A; Snoeys, J, 2021
)
0.62
"The goal of the present study was: 1) to determine brain concentrations of MDPV and its metabolites, 3,4-dihydroxypyrovalerone (3,4-catechol-PV) and 4-hydroxy-3-methoxy-pyrovalerone (4-OH-3-MeOPV), after administration of MDPV, and 2) to relate brain pharmacokinetic measures to pharmacodynamic endpoints in the same subjects."( Brain Concentrations of MDPV and its Metabolites in Male Rats: Relationship to Pharmacodynamic Effects.
Acosta, T; Baumann, MH; Chojnacki, MR; Concheiro, M; Elmore, JS; Rice, KC; Suzuki, M; Towler, S, 2022
)
0.72

Compound-Compound Interactions

ExcerptReferenceRelevance
"5 g of levodopa daily for up to six months and in 30 patients receiving levodopa (800-1,000 mg) combined with a dopa decarboxylase inhibitor, benserazide (200-250 mg)."( Urinary excretion of monoamines and their metabolites in patients with Parkinson's disease. Response to long-term treatment with levodopa alone or in combination with a dopa decarboxylase inhibitor and clinical correlations.
Rinne, UK; Siirtola, T; Sonninen, V, 1975
)
0.25
" However, PCP in combination with morphine produced an increase in met-enkephalin levels and a decrease in HVA levels."( Effects of phencyclidine in combination with morphine on the levels of met-enkephalin, dopamine, DOPAC and HVA in discrete brain areas of mice.
Furukawa, H; Hiramatsu, M; Kameyama, T; Nabeshima, T, 1985
)
0.27
"The time course of the effects of ethanol alone and in combination with the selective alpha 2-adrenoceptor agonist dexmedetomidine and the alpha-adrenoceptor antagonist atipamezole was studied in NIH-Swiss mice."( The effects of ethanol in combination with the alpha 2-adrenoceptor agonist dexmedetomidine and the alpha 2-adrenoceptor antagonist atipamezole on brain monoamine metabolites and motor performance of mice.
Björn, M; Idänpään-Heikkilä, JJ; Seppälä, T, 1995
)
0.29
"5Gy) TBI, C57BL/6 mice were administered with MPTP (15mg/kg, four times, 2h apart) intraperitoneally (i."( Potential mechanisms of neuroprotection induced by low dose total-body gamma-irradiation in C57 mice administered with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).
Guo, Q; Li, S; Liang, Y; Su, B; Wen, C; Zhang, Y, 2009
)
0.35

Bioavailability

ExcerptReferenceRelevance
" However, in both cases, levels of corticosterone in plasma were dramatically elevated, clearly demonstrating the bioavailability of the kappa agonists."( The endogenous kappa agonist, dynorphin(1-13), does not alter basal or morphine-stimulated dopamine metabolism in the nigrostriatal pathway of the rat.
Cosi, C; Iyengar, S; Kim, HS; Wood, PL, 1987
)
0.27
" Pharmacokinetic investigations showed that the oral bioavailability of tacrine was low and greatly varying between subjects."( Clinical experiences and biochemical findings with tacrine (THA).
Ahlin, A; Hassan, M; Junthé, T; Nybäck, H, 1993
)
0.29
" These findings support the notion that tolcapone has the ability to enhance striatal dopamine neurotransmission by increasing L-dopa bioavailability through peripheral and central inhibition of L-dopa O-methylation, as well as by blocking the central conversion of dopamine into 3-methoxytyramine."( Effects of tolcapone, a novel catechol-O-methyltransferase inhibitor, on striatal metabolism of L-dopa and dopamine in rats.
Da Prada, M; Napolitano, A; Zürcher, G, 1995
)
0.29
" Peripheral COMT inhibition with entacapone increased significantly the bioavailability of levodopa and prolonged its antiparkinsonian effect after a single dose and after repeated dosing for 4 weeks."( Effect of one month's treatment with peripherally acting catechol-O-methyltransferase inhibitor, entacapone, on pharmacokinetics and motor response to levodopa in advanced parkinsonian patients.
Rinne, UK; Ruottinen, HM, 1996
)
0.29
"We have recently demonstrated, in humans, the bioavailability of hydroxytyrosol (3,4-dihydroxyphenylethanol; HT), one of the major antioxidant components of virgin olive oil."( Urinary excretion of olive oil phenols and their metabolites in humans.
Caruso, D; Galli, C; Galli, G; Patelli, R; Visioli, F, 2001
)
0.31
" The cleavage of DFA by human intestinal microbiota, which depended on their coupling type, may affect both the bioavailability of DFA and the degradability of DFA-coupled fiber in the gut."( Conversion of dehydrodiferulic acids by human intestinal microbiota.
Blaut, M; Braune, A; Bunzel, M; Yonekura, R, 2009
)
0.35
" However, the bioavailability of the most important of these compounds, hydroxytyrosol (HT), and its transformation into derivatives within the organism after oral intake are still not completely understood, requiring further in vivo research."( Gender differences in plasma and urine metabolites from Sprague-Dawley rats after oral administration of normal and high doses of hydroxytyrosol, hydroxytyrosol acetate, and DOPAC.
Auñón, D; Domínguez-Perles, R; Ferreres, F; Gil-Izquierdo, A, 2017
)
0.46
"Plasma and urine levels indicated that although the three compounds are efficiently absorbed in the gastrointestinal tract and show similar metabolism, the bioavailability is strongly dependent on the derivative considered, dosage, and gender."( Gender differences in plasma and urine metabolites from Sprague-Dawley rats after oral administration of normal and high doses of hydroxytyrosol, hydroxytyrosol acetate, and DOPAC.
Auñón, D; Domínguez-Perles, R; Ferreres, F; Gil-Izquierdo, A, 2017
)
0.46
" Many flavonoids have poor bioavailability and thus low circulating concentrations."( Common gut microbial metabolites of dietary flavonoids exert potent protective activities in β-cells and skeletal muscle cells.
Allen, ME; Bitner, BF; Brown, DA; Fausnacht, DW; Herring, JA; Hulver, MW; Johnson, DK; Kener, KB; McMillan, RP; Neilson, AP; Ray, JD; Tellez Freitas, CM; Tessem, JS; Thomson, AH; Tueller, JA; Weber, KS, 2018
)
0.48

Dosage Studied

The striatal concentration of dopamine (DA), norepinephrine (NE), and homovanillic acid (HVA) was assessed in adult male rabbits exposed to styrene vapours or dosed with mandelic acid. The AUC of 3-O-methyldopa decreased by 45% and aUC of HVA by 21% after 4 weeks' dosing with entacapone.

ExcerptRelevanceReference
" Bromocriptine at low dosage seems to act as a partial dopamine antagonist, with phenothiazine-like effects, and at higher doses it acts as a direct dopamine-receptor stimulating agent."( Bromocriptine and dopaminergic function in Huntington disease.
Albano, C; Besio, G; Loeb, C; Roccatagliata, G, 1979
)
0.26
"The effect of various antipsychotic drugs on the blockade of dopaminergic receptors in striatum and limbic forebrain was examined by establishing dose-response curves for the increase in HVA and for the antagonism of d-amphetamine-induced rotation in rats with unilateral lesions of the substantia nigra."( On the significance of the increase in homovanillic acid (HVA) caused by antipsychotic drugs in corpus striatum and limbic forebrain.
Dingell, JV; Hill, H; Robinson, SE; Setler, P; Stawarz, RJ; Sulser, F, 1975
)
0.52
" Similarly, a shift to the left of the haloperidol dose-response curve for the increase in striatal dopamine metabolite levels was observed in rats treated subacutely with the ester as compared to control rats."( Subsensitivity of striatal and mesolimbic dopamine target cells after repeated treatment with apomorphine dipivaloyl ester.
Scatton, B; Worms, P, 1978
)
0.26
" In the present trial, the 779704 combination was maintained without any alterations in dosage for six months, and the therapeutic effect persisted unchanged."( Potentiation by metyrosine of thioridazine effects in chronic schizophrenics. A long-term trial using double-blind crossover technique.
Carlsson, A; Roos, BE; Skott, A; Wålinder, J, 1976
)
0.26
" Even so, plasma levodopa concentration correlates significantly with dosage size in a large parkinsonian population and also coincides with therapeutic response in many, but not all, patients."( Clinical pharmacokinetics of levodopa in parkinson's disease.
Bianchine, JR; Shaw, GM, 1976
)
0.26
" The dose-response curves for the two last-mentioned dopamine metabolites closely follow those for MAO A and dopamine-deaminating activity, whether clorgyline or deprenil was used as MAO inhibitor."( Preferential deamination of dopamine by an A type monoamine oxidase in rat brain.
Delini-Stula, A; Maître, L; Waldmeier, PC, 1976
)
0.26
" Dose-response curves and time-action curves were generated."( Differential sensitivity of two dopaminergic structures in rat brain to haloperidol and to clozapine.
Stanley, ME; Watson, E; Wilk, S, 1975
)
0.25
", were much higher in chronically dosed animals."( Effects of chronic oral administration on the disposition of laevodopa and its major metabolites in the plasma of the rat.
Cheng, LK; Fung, HL, 1975
)
0.25
" Abnormal movements accompany an overdose but regress when the dosage is decreased."( [Dopa-sensitive dystonia].
Aicardi, J; Goutières, F; Rondot, P; Ziegler, M, 1992
)
0.28
" However, whereas this dosage regimen revealed a profound behavioral sensitization in response to challenge with amphetamine (2."( In vivo microdialysis reveals a diminished amphetamine-induced DA response corresponding to behavioral sensitization produced by repeated amphetamine pretreatment.
Kuczenski, R; Segal, DS, 1992
)
0.28
" Dose-response curves for DA and 5-HT release indicated no marked difference in the sensitivity to ethanol between the lines."( Ethanol enhances the release of dopamine and serotonin in the nucleus accumbens of HAD and LAD lines of rats.
Li, TK; Lumeng, L; McBride, WJ; Yoshimoto, K, 1992
)
0.28
" In time course and dose-response experiments with ET-1 and in comparisons with ET-3, the volume of the lesions has been determined based mainly on the disappearance of striatal nerve cells, using a computer assisted morphometrical analysis."( Involvement of local ischemia in endothelin-1 induced lesions of the neostriatum of the anaesthetized rat.
Agnati, LF; Cintra, A; Fuxe, K; Goiny, M; Hallström, A; Kurosawa, N; Rosén, L; Ungerstedt, U, 1992
)
0.28
" To examine the subacute neurochemical changes induced by low doses of MPTP and 4'-amino-MPTP, dose-response studies of these compounds were carried out in the dog, using 6- and 3-week survival times for these two compounds, respectively."( Prolonged alterations in canine striatal dopamine metabolism following subtoxic doses of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and 4'-amino-MPTP are linked to the persistence of pyridinium metabolites.
Johannessen, JN; Markey, SP; Sobotka, TJ; Weise, VK, 1991
)
0.28
" The shapes of the dose-response functions differed considerably between the drugs."( In vivo characterization of locally applied dopamine uptake inhibitors by striatal microdialysis.
Damsma, G; Fibiger, HC; Nomikos, GG; Wenkstern, D, 1990
)
0.28
" Acute tetrahydroaminoacridine (THA) dosing caused lower brain (68%) and higher plasma (90%) ChE inhibition than the other drugs studied and increased levels of brain dihydroxyphenylacetic acid (DOPAC) (236%), homovanillic acid (HVA) (197%) and 5-hydroxyindoleacetic acid (5-HIAA) (130%)."( Effect of acute and chronic cholinesterase inhibition on biogenic amines in rat brain.
Shillcutt, S; Soininen, H; Unni, L, 1990
)
0.47
" More importantly, if a subacute dosing regimen (every 12 hours for 4 days) was utilized, the combination of S-amphetamine with MDAI resulted in a marked long-term decrease in the levels of cortical, hippocampal and striatal 5-HT, 5-HIAA and the number of 5-HT uptake sites."( Serotonin neurotoxicity in rats after combined treatment with a dopaminergic agent followed by a nonneurotoxic 3,4-methylenedioxymethamphetamine (MDMA) analogue.
Huang, XM; Johnson, MP; Nichols, DE, 1991
)
0.28
" In 46 children from this sample it was dosed plasmatic cortisol and the urinary excretion of catecholamine, VMA, HVA and 5-HIAA."( Biochemical correlate of depression in children.
Basques, JC; Fabre, ZL; Fernandes, ML; Furtado, CR; Lippi, JR; Lombardi, AB; Peixoto, CC; Queiroz, EA; Soares, TA, 1991
)
0.28
" The results suggest that the selected dosage schedule produces a widespread and lasting neuronal degeneration closely resembling the neurochemical pathology of Parkinson's disease."( Extensive loss of brain dopamine and serotonin induced by chronic administration of MPTP in the marmoset.
De Ceballos, ML; Del Río, J; Herrero, MT; Luquin, MR; Obeso, JA; Oset, C; Pérez-Otaño, I, 1991
)
0.28
" Thus, dose-response and time-response studies were conducted in order to assess the effects of this drug on monoaminergic and neuropeptide systems in extrapyramidal and limbic structures."( Neurochemical effects of an acute treatment with 4-methylaminorex: a new stimulant of abuse.
Bunker, CF; Bush, LG; Gibb, JW; Hanson, GR; Johnson, M, 1990
)
0.28
" dosing of TA-870 (30 mg/kg) were DA greater than homovanillic acid (HVA) greater than 3,4-dihydroxyphenylacetic acid (DOPAC) greater than 3-hydroxyphenylacetic acid (3-HPAC)."( Metabolism of a new orally active dopamine prodrug, N-(N-acetyl-L-methionyl)-O,O-bis(ethoxycarbonyl)dopamine (TA-870) and dopamine after oral administration to rats and dogs.
Endo, H; Komatsu, K; Sugawara, Y; Takaiti, O; Yoshikawa, M, 1990
)
0.53
" We sought to determine whether daily versus weekly dosing of haloperidol for 3 weeks produced distinct effects on DA, dihydroxyphenylacetic acid (DOPAC), and homovanillic acid (HVA) concentrations in multiple brain areas."( Sensitization versus tolerance to the dopamine turnover-elevating effects of haloperidol: the effect of regular/intermittent dosing.
Barnes, DE; Bellows, EP; Csernansky, JG; Lombrozo, L, 1990
)
0.48
"Amiflamine, a drug reported to be a reversible inhibitor of monoamine oxidase type A (MAO-A) selective for serotonergic neurons in rodents, was administered to rhesus monkeys over a 12-fold dosage range (0."( The effects of amiflamine on cerebrospinal fluid amine metabolites in the rhesus monkey.
Garrick, NA; Linnoila, M; Murphy, DL; Seppala, T, 1985
)
0.27
" injection of the drug at a dosage rate of 20 micrograms/kg."( Neurochemical changes in the brain and spinal cord of sheep: a basis for the immobilizing action of etorphine.
Kania, BF, 1985
)
0.27
" However, the dose-response curve for the substance P effect had a biphasic shape."( Differential modulation of striatal dopamine release by intranigral injection of gamma-aminobutyric acid (GABA), dynorphin A and substance P.
Herrera-Marschitz, M; Hökfelt, T; Reid, M; Terenius, L; Ungerstedt, U, 1988
)
0.27
" Decreases in 5-HIAA persisted throughout the chronic dosing regimen (36 days), while dopamine metabolites returned to control levels within 8 days."( Neurochemical changes in pigeon cerebrospinal fluid during chronic administration of buspirone or 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT).
Barrett, JE; Nader, MA, 1989
)
0.28
" Lumbar punctures were carried out prior to treatment and at the end of each dosage regimen and cerebrospinal fluid (CSF) evaluated for concentrations of free and total GABA, homocarnosine (GABA-histidine dipeptide), homovanillic acid (HVA), 5-hydroxyindole acetic acid (5-HIAA) and vigabatrin."( The effect of different vigabatrin treatment regimens on CSF biochemistry and seizure control in epileptic patients.
Ben-Menachem, E; Dahlgren, L; Haegele, KD; Hardenberg, J; Huebert, N; Mumford, JP; Persson, LI; Schechter, PJ, 1989
)
0.46
" L-DOPA administration, consisting of a daily dosage of 600 mg plus 150 mg aromatic L-amino acid decarboxylase inhibitor was continued in all cases for at least 3 months."( Unresponsiveness to L-DOPA in parkinsonian patients: a study of homovanillic acid concentration in the cerebrospinal fluid.
Araki, H; Kondo, T; Muramoto, S; Narabayashi, H; Nishi, K; Takubo, H, 1989
)
0.52
" The results suggest, the BH4 in the dosage used, is not effective in the treatment of Parkinson's disease."( Tetrahydrobiopterin and Parkinson's disease.
Dissing, IC; Gerdes, AM; Güttler, F; Lou, H; Lykkelund, C; Pakkenberg, H; Rasmussen, V, 1989
)
0.28
" There was no dose-response effect of sulpiride on serum levels of the monoamine metabolites or the amino acids."( Monoamine metabolites and amino acids in serum from schizophrenic patients before and during sulpiride treatment.
Alfredsson, G; Wiesel, FA, 1989
)
0.28
"50 pmol/ml) did not change after 1 wk of Li dosing (1."( Differences in lithium effects in depressed and healthy subjects.
Karoum, F; Linnoila, M; Potter, WZ; Ross, RJ; Rudorfer, MV, 1985
)
0.27
" The dosage of both zimeldine and alaproclate was 200 mg daily."( Alaproclate a novel antidepressant? A biochemical and clinical comparison with zimeldine.
Aberg-Wistedt, A; Alvariza, M; Bertilsson, L; Malmgren, R; Wachtmeister, H, 1985
)
0.27
" Although not statistically significant, the VMA excretion was also noted to be moderately elevated; however, it is recognized that the present study was unable to establish a highly significant dose-response relationship between lead exposure and HVA excretion, as has been reported earlier in lead-poisoned children."( Neurochemical effect of lead exposure: a study on catecholamine metabolism.
Chia, KS; Koh, D; Ong, CN; Saijoh, K, 1989
)
0.28
" The effect of NADH was dependent on the dosage and the severity of the case."( Nicotinamidadenindinucleotide (NADH): the new approach in the therapy of Parkinson's disease.
Birkmayer, GJ; Birkmayer, W,
)
0.13
" Subsequent challenge with haloperidol indicated a significant decrease in responsiveness to haloperidol-induced release of DA, but not HVA, in chronically dosed rats."( Repeated haloperidol administration changes basal release of striatal dopamine and subsequent response to haloperidol challenge.
Hong, JS; Stachowiak, MK; Tilson, H; Zhang, W, 1989
)
0.28
"The striatal concentration of dopamine (DA), norepinephrine (NE), and homovanillic acid (HVA) was assessed in adult male rabbits exposed to styrene vapours or dosed with mandelic acid (MA), phenylglyoxylic acid (PGA) and phenylglycine (PG)."( Styrene metabolism and striatal dopamine depletion in rabbits.
Falzoi, M; Franchini, I; Lucertini, S; Mutti, A; Romanelli, A, 1985
)
0.5
" Lithium by itself in acute (2 meq kg-1, 24 and 4 h before test) or extended (2 meq kg-1 daily for 9 days) dosage had little effect on horizontal or vertical activity or levels of DA or DOPAC."( Hyperactivity induced by dexamphetamine/chlordiazepoxide mixtures in rats and its attenuation by lithium pretreatment: a role for dopamine?
Aylmer, CG; Steinberg, H; Webster, RA, 1987
)
0.27
"The effects of different dosing paradigms for the administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) were investigated in C57-black and CF-W albino mice."( The influence of dose and dosing interval on MPTP-induced dopaminergic neurotoxicity in mice.
Heikkila, RE; Sonsalla, PK, 1986
)
0.27
"The effects of long-term dosing with tiapride for 21 days on barin dopamine receptors and dopamine turnover were compared with those of sulpiride and haloperidol."( Effect of long-term dosing with tiapride on brain dopamine receptors and metabolism in rats. Comparative study with sulpiride and haloperidol.
Kohjimoto, Y; Kuwaki, T; Nomura, Y; Ono, T; Satoh, H; Shibayama, F; Shirakawa, K, 1987
)
0.27
" Bromocriptine did not show this effect, as the dose-response relationships for HVA decrease, for induction of stereotypy and for the decrease in specific (-)DP-5,6-ADTN binding were all virtually equal to each other."( S(-)DP-5,6-ADTN as an in vivo dopamine receptor ligand: relation between displacement by dopamine agonists and their pharmacological effects.
Feenstra, MG; Grol, CJ; Lewis, MH; Mailman, RB; Rollema, H; Staples, L, 1986
)
0.27
" Adult male Wistar-derived rats were exposed to a single dose of corn oil, either alone or containing equal amounts of Aroclors 1254 and 1260 at a dosage of 500 or 1000 mg/kg."( Oral dosing of rats with polychlorinated biphenyls increases urinary homovanillic acid production.
Brosch, KO; Bush, B; Seegal, RF, 1985
)
0.5
" These reductions were prevented by pretreatment with homocysteine at a dosage which had been shown to inhibit protein carboxyl and other methylation reactions in brain."( Homocysteine prevents apomorphine-induced decreases in dopamine metabolites.
Salama, AI; Saller, CF, 1985
)
0.27
"Biogenic amines in pons and striatum have been dosed in twenty-four months old Wistar male rats."( [Biochemical changes in 24-month-old Wistar rats].
Della Zuana, O; Duhault, J; Lonchampt, M; Roman, F; Saint Romas, G, 1984
)
0.27
" administration of lisuride at the dosage known to be ineffective on the postsynaptic dopamine receptor."( [Suppressive effects of lisuride on the synthesis, release and metabolism of dopamine in rat brain].
Azuma, H; Iwai, K; Kikuta, M; Liu, HJ; Oshino, N; Sato, K, 1982
)
0.26
"In a single-blind study, 12 men (mean age 63 years) with senile dementia were given nafronyl in a dosage of 100 mg eight times daily for a week, followed by 100 mg four times daily for 12 weeks."( Effect of nafronyl on lactate and pyruvate in the cerebrospinal fluid of patients with senile dementia.
Berger, PA; Hollister, LE; Tinklenberg, JR; Yesavage, JA, 1982
)
0.26
" In polyphasic sleepers like cats, we did not observe tryptophan's hypnotic effect with any dosage used (10, 30 or 135 mg/kg)."( L-Tryptophan's effects on brain chemistry and sleep in cats and rats: a review.
Radulovacki, M, 1982
)
0.26
" The suggested importance of treatment schedule rather than cumulative drug dosage in the development of tolerance to haloperidol may have significance to long-term side effects of chronic neuroleptic treatment such as tardive dyskinesia and clinical issues such as drug holidays."( Treatment schedule as a determinant of the development of tolerance to haloperidol.
Carey, RJ; DeVeaugh-Geiss, J, 1984
)
0.27
" Apomorphine does not produce the shaped dose-response activity curve found with systemic injections."( Intracerebroventricular apomorphine alleviates spontaneous forgetting and increases cortical noradrenaline.
Grecksch, G; Leviel, V; Sara, SJ, 1984
)
0.27
" Urinary HVA dosage was performed on samples of urine taken after a 48-h tyrosine-free diet."( [Relation between auditory evoked potentials (presence, amplitude) during sound and light conditioning and levels of dopamine derivatives in infantile autism].
Barthelemy, C; Bruneau, N; Garreau, B; Lelord, G; Martineau, J; Tanguay, P, 1984
)
0.27
" The time course of H2O2 release by mouse peritoneal and bone marrow-derived macrophages and by human neutrophils was determined following stimulation with zymosan particles or phorbol myristate acetate, and the dependence of H2O2 release on cell number and stimulus dosage was studied."( Assay of H2O2 production by macrophages and neutrophils with homovanillic acid and horse-radish peroxidase.
Baggiolini, M; Cooper, PH; Ruch, W, 1983
)
0.51
" The cerebral content of dopamine (DA), noradrenaline (NA) and homovanillic acid (HVA) was determined after some dosage schedules."( Participation of prostaglandins in the action of kinins on the central dopaminergic system in the rat. I. The action of kinins on the central dopaminergic system after pretreatment with indomethacin.
Kościelak, M; Moniuszko-Jakoniuk, J; Wiśniewski, K,
)
0.37
" Plasma prolactin levels, initially high, increased when the dosage was increased to 100 mg/day but did not increase further."( High doses of haloperidol in schizophrenia. A clinical, biochemical, and pharmacokinetic study.
Bianchetti, G; Cuche, H; Loo, H; Morselli, PL; Scatton, B; Zarifian, E, 1982
)
0.26
" In neither patient, the increase in haloperidol dosage affected paranoid symptoms."( [Use of haloperidol in high doses in schizophrenia. Clinical, biochemical and pharmacokinetic study].
Bianchetti, G; Cuche, H; Loo, H; Morselli, PL; Scatton, B; Zarifian, E, 1982
)
0.26
" In contrast, there seemed to be a correlation between dopamine turnover and optimum dosage of l-DOPA."( [Value of the probenecid test in the diagnosis and treatment of parkinson disease].
Mendlewicz, J; Noel, G; Vanderheyden, JE,
)
0.13
" In the second phase of this study the same 12 PDD patients were treated with GAP at a daily dosage of 250 lipasemic-releasing units for a period of 1 month and it was found that all four biochemical parameters shifted towards normal values during therapy with the changes in CSF 5-hydroxy-indole acetic acid levels attaining statistical significance."( Glycosaminoglycan polysulfate in primary degenerative dementia. Pilot study of biologic and clinical effects.
Ban, TA; Parnetti, L; Senin, U, 1995
)
0.29
" The current study evaluated the dose-response relationships of MDMA (1."( Oral administration of 3,4-methylenedioxymethamphetamine (MDMA) produces selective serotonergic depletion in the nonhuman primate.
Ali, SF; Bailey, JR; Binienda, Z; Ferguson, SA; Newport, GD; Paule, MG; Scallet, AC; Slikker, W,
)
0.13
" Here, adult female rats were dosed with PCP (10 mg/kg, IP), or (+)-MK-801 (0."( Phencyclidine and (+)-MK-801-induced circling preference: correlation with monoamine levels in striatum of the rat brain.
Ali, SF; Bracha, HS; Newport, GD,
)
0.13
" Dosage of concurrent neuroleptics was fixed at least 3 weeks prior to the trial and was unchanged throughout the study period."( B-HT 920, a dopamine D2 agonist, in the treatment of negative symptoms of chronic schizophrenia.
Inoue, T; Koyama, T; Matsubara, S; Ohmori, T; Yamashita, I, 1993
)
0.29
" Eighteen-day-old rats were 35% and 63% more sensitive than adults to the effects of haloperidol on striatal and accumbens turnover and had steeper dose-response curves."( Developmental differences in acute nigrostriatal and mesocorticolimbic system response to haloperidol.
Baldessarini, RJ; Barber, NI; Campbell, A; Gallitano, AL; Gelbard, HA; Marsh, E; Teicher, MH, 1993
)
0.29
" A dose-response effect of apomorphine on extracellular dopamine was observed in all age groups except at 10-11 days of age."( The ontogeny of apomorphine-induced alterations of neostriatal dopamine release: effects on spontaneous release.
Andersen, SL; Gazzara, RA, 1993
)
0.29
" MPTP produced a slight but significant decrease of DA only 4 hours post dosing on PND 23."( Age-related susceptibility to MPTP-induced neurotoxicity in mice.
Ali, SF; David, SN; Newport, GD, 1993
)
0.29
" Our results suggest that brofaromine at the clinically used dosage of 150 mg/day does indeed inhibit 5-HT uptake, as evidenced by measurements of 3H-paroxetine binding to platelets."( Serotonin uptake inhibition by the monoamine oxidase inhibitor brofaromine.
Feldtrauer, JJ; Germer, M; Graf, T; Howald, H; Waldmeier, PC, 1993
)
0.29
" After an initial acute dose-response assessment, escalating doses of MDMA (0."( Behavioral and neurochemical effects of chronic methylenedioxymethamphetamine (MDMA) treatment in rhesus monkeys.
Ali, SF; Allen, RR; Frederick, DL; Gillam, MP; Paule, MG; Slikker, W,
)
0.13
" Animals were dosed with PCP (15 mg/kg, ip) its congener (+) MK-801 (0."( Drug-induced circling preference in rats. Correlation with monoamine levels.
Ali, SF; Gough, B; Kordsmeier, KJ,
)
0.13
" The AUC of 3-O-methyldopa decreased by 45% and AUC of homovanillic acid by 21% after 4 weeks' dosing with entacapone."( Effect of one month's treatment with peripherally acting catechol-O-methyltransferase inhibitor, entacapone, on pharmacokinetics and motor response to levodopa in advanced parkinsonian patients.
Rinne, UK; Ruottinen, HM, 1996
)
0.54
" Part 1 of the study established a dose-response curve and the temporal pattern of GSH loss and recovery in the substantia nigra and striatum following acute BSO treatment."( Effect of buthionine sulfoximine, a synthesis inhibitor of the antioxidant glutathione, on the murine nigrostriatal neurons.
Andersen, JK; Hamill, RW; Harnish, P; Hom, DG; Lee, FY; McNeill, TH; Mo, JQ, 1996
)
0.29
" The pharmacokinetic parameters of moclobemide and its metabolites changed on multiple dosing but were not influenced to a relevant extent by concomitant administration of selegiline."( Pharmacokinetic-pharmacodynamic interactions between two selective monoamine oxidase inhibitors: moclobemide and selegiline.
Dingemanse, J; Kettler, R; Kneer, J; Korn, A; Koulu, M; Wallnöfer, A; Zürcher, G, 1996
)
0.29
" The glutamate- or NAAG-mediated blockage of calcium channels showed indistinguishable dose-response curves, with K1/2 = 388 and 350 nM for glutamate and NAAG, respectively."( Glutamate and N-acetylaspartylglutamate block HVA calcium currents in frog olfactory bulb interneurons via an mGluR2/3-like receptor.
Bischofberger, J; Schild, D, 1996
)
0.29
"A 79-year-old male suffering from Shy-Drager syndrome was treated with a daily dosage of 300 mg of L-threo-3,4-dihydroxyphenylserine (L-DOPS)."( [Monoamine imbalance of the central nervous system in a case of Shy-Drager syndrome with recurrent attacks of a neuroleptic malignant syndrome].
Hamamoto, M; Miyazaki, T; Otsubo, K; Terashi, A; Ueda, M, 1996
)
0.29
" A dosing regiment of 30 mg/kg MPTP once a day for 3 days (90 mg/kg total dose) in 4-month-old male and female CD-1 mice led to a significant depletion of striatal dopamine in both sexes."( The dopamine-depleting effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in CD-1 mice are gender-dependent.
Ali, SF; Cadet, JL; Freyaldenhoven, TE, 1996
)
0.29
" Generalized tonic-clonic seizures observed in EP mice were inhibited by valproate, administered 1 h prior to testing, in a dose-response fashion."( Effects of valproate on amino acid and monoamine concentrations in striatum of audiogenic seizure-prone Balb/c mice.
Alexiuk, NA; Vriend, JP, 1996
)
0.29
" These results indicate that in vervet monkey striatum, an acute Amp or MeAmp drug dosage produces extensive striatal dopamine system neurotoxicity."( Recovery of striatal dopamine function after acute amphetamine- and methamphetamine-induced neurotoxicity in the vervet monkey.
Huang, SC; Lacan, G; Melega, WP; Phelps, ME; Raleigh, MJ; Stout, DB, 1997
)
0.3
" In a second experiment, mice were dosed according to the same paradigm and were perfused at 18 h after treatment for immunohistochemical analysis."( Methamphetamine-induced hyperthermia in mice: examination of dopamine depletion and heat-shock protein induction.
Ali, SF; Freyaldenhoven, TE; Kuperman, DI; Schmued, LC, 1997
)
0.3
" Nine were administered N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) at a dosage of 1 mg/kg/day, SC, for 6 days, the last five pigs received saline injections for 6 days."( MPTP-induced Parkinsonism in minipigs: A behavioral, biochemical, and histological study.
Harajehi, JB; Jensen, LH; Mikkelsen, M; Møller, A; Pakkenberg, H; Pedersen, A,
)
0.13
" 18-Methoxycoronaridine produced a downward shift in the entire morphine dose-response curve without any displacement to the left or right."( Attenuation of the reinforcing efficacy of morphine by 18-methoxycoronaridine.
Glick, SD; Maisonneuve, IM, 1999
)
0.3
"These results suggest that pretreatment plasma HVA could be useful for dosing antipsychotics."( Pretreatment plasma HVA and haloperidol response in acute mania.
Bebe, R; Chang, WH; Charles, O; Chou, JC; Cooper, TB; Czobor, P; Lane, HY; Stone, DL; Tuma, I, 2000
)
0.31
" Although increasing the dosage of d-METH (20 to 80 mg/kg) did increase the GFAP response (100% over control), it was still well below that usually exhibited at the usual neurotoxic dosage (300-400% over control) in fully mature mice."( Age as a susceptibility factor in the striatal dopaminergic neurotoxicity observed in the mouse following substituted amphetamine exposure.
Ali, SF; Miller, DB; O'Callaghan, JP, 2000
)
0.31
" Rats that did not become hyperthermic when dosed with 15 mg/kg AMPH in a cold environment (10 degrees C) exhibited some hyperactivity and stereotypic behavior, but not overt convulsive behavior."( Seizure activity and hyperthermia potentiate the increases in dopamine and serotonin extracellular levels in the amygdala during exposure to d-amphetamine.
Bowyer, JF; Tor-Agbidye, J; Yamamoto, B, 2001
)
0.31
" The levels declined by increasing the dosage of the extract to 200 mg/kg and 300 mg/kg, however, these levels remained higher than the control group."( Central nervous system stimulatory action from the root extract of Plumbago zeylanica in rats.
Bopaiah, CP; Pradhan, N, 2001
)
0.31
" A treatment history of high AMPH dosage was associated with a marked sensitization of the exploratory behavior in adults, whereas it induced a quite opposite profile in periadolescents."( Striatal dopamine sensitization to D-amphetamine in periadolescent but not in adult rats.
Laviola, G; Pascucci, T; Pieretti, S, 2001
)
0.31
" An inhibition of morphine-induced increases in dopamine could be interpreted as either antagonism or potentiation depending the shape of the morphine dose-response curve."( Biphasic dose-related effects of morphine on dopamine release.
Glick, SD; Maisonneuve, IM; Warner, LM, 2001
)
0.31
" Recently it was shown that hydroxytyrosol and five metabolites were excreted in urine when hydroxytyrosol was dosed intravenously or orally in an olive oil solution to rats."( Structural characterization of the metabolites of hydroxytyrosol, the principal phenolic component in olive oil, in rats.
Hayball, PJ; Stupans, I; Tuck, KL, 2002
)
0.31
" The remaining animals were dosed ip with 0 (corn oil vehicle; 2 ml/kg), 100, 200, or 400 mg/kg CS2."( Disassociation of carbon disulfide-induced depression of flash-evoked potential peak N166 amplitude and norepinephrine levels.
Graff, JE; Herr, DW, 2003
)
0.32
" Similarly to what has been reported concerning nicotine, the dose-response curve of epibatidine to increase the dopamine output in the caudate-putamen was bell-shaped and clearly differed from that in the accumbens."( Comparison of the effects of nicotine and epibatidine on the striatal extracellular dopamine.
Ahtee, L; Janhunen, S, 2004
)
0.32
"The technique of 'binge' dosing (several doses in one session) by recreational users of 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) requires evaluation in terms of its consequences on the acute hyperthermic response and long-term neurotoxicity."( Effect of repeated ('binge') dosing of MDMA to rats housed at normal and high temperature on neurotoxic damage to cerebral 5-HT and dopamine neurones.
Colado, MI; Elliott, JM; Green, AR; O'shea, E; Saadat, KS; Sanchez, V, 2004
)
0.32
" In order to evaluate the anabolic or toxic effects of the dosing regimens used, selected peripheral effects were monitored as well."( The effect of sub-chronic nandrolone decanoate treatment on dopaminergic and serotonergic neuronal systems in the brains of rats.
Ellermaa, S; Kankaanpää, A; Karila, T; Kurling, S; Seppälä, T, 2005
)
0.33
" BMAA perfusion produced a dose-response increase in the extracellular output of dopamine."( Acute perfusion of BMAA in the rat's striatum by in vivo microdialysis.
Cano, J; Machado, A; Matarredona, ER; Santiago, M, 2006
)
0.33
" Finally, after determination of basal levels of 3,4-dihydroxyphenylacetic acid (DOPAC), homovanillic acid (HVA), and 5-hydroxyindole-3-acetic acid (5-HIAA) in the rats, the rats were dosed with benserazide followed by l-3,4-dihydroxyphenylalanine (l-DOPA)."( Evaluation of an osmotic pump for microdialysis sampling in an awake and untethered rat.
Cooper, JD; Davies, MI; Heppert, KE; Lunte, SM, 2007
)
0.56
" Here, we present a case of PTPS deficiency which showed a more significant correlation of dosage of L-Dopa/carbidopa with serum prolactin levels than with CSF HVA levels."( A case of 6-pyruvoyl-tetrahydropterin synthase deficiency demonstrates a more significant correlation of L-Dopa dosage with serum prolactin levels than CSF homovanillic acid levels.
Kanazawa, M; Kitani, Y; Kohno, Y; Ogawa, A; Shintaku, H; Takayanagi, M, 2008
)
0.54
" Time of diagnosis, dosage of BH4 and neurotransmitter precursors, folinic acid substitution, and levels of 5-hydroxyindoleacetic acid (5HIAA) and homovanillic acid (HVA) in cerebrospinal fluid (CSF) are essential parameters in the follow-up of patients."( Outcome and long-term follow-up of 36 patients with tetrahydrobiopterin deficiency.
Ballhausen, D; Baumgartner, MR; Blau, N; Fiori, L; Giovannini, M; Hoffmann, GF; Ibel, H; Jäggi, L; Ponzone, A; Porta, F; Santer, R; Schuler, A; Wendel, U; Zurflüh, MR, 2008
)
0.55
"Effects on neurotransmitter/metabolite concentrations were assessed in male rats following single oral doses of LY2140023 monohydrate (microdiasylates from the prefrontal cortex), single intraperitoneal injection of LY404039 [cerebrospinal fluid (CSF)], or LY2140023 monohydrate dosed once daily for 7 days (CSF)."( Effects of a novel mGlu₂/₃ receptor agonist prodrug, LY2140023 monohydrate, on central monoamine turnover as determined in human and rat cerebrospinal fluid.
Ackermann, B; Anderson, S; Ayan-Oshodi, M; Dean, R; Eckstein, J; Ho, M; Jackson, K; Lowe, S; McKinzie, D; Natanegara, F; Perry, K; Svensson, K; Yuen, E, 2012
)
0.38
"Rat studies: Acute dosing with LY2140023 monohydrate resulted in significant dose-dependent increases in extracellular concentrations of dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA), but not 5-hydroxyindoleacetic acid (5-HIAA), in the prefrontal cortex."( Effects of a novel mGlu₂/₃ receptor agonist prodrug, LY2140023 monohydrate, on central monoamine turnover as determined in human and rat cerebrospinal fluid.
Ackermann, B; Anderson, S; Ayan-Oshodi, M; Dean, R; Eckstein, J; Ho, M; Jackson, K; Lowe, S; McKinzie, D; Natanegara, F; Perry, K; Svensson, K; Yuen, E, 2012
)
0.57
"LY2140023 monohydrate and/or LY404039 dosing potently affected dopamine turnover and also significantly affected serotonin turnover in the human and rat central nervous systems."( Effects of a novel mGlu₂/₃ receptor agonist prodrug, LY2140023 monohydrate, on central monoamine turnover as determined in human and rat cerebrospinal fluid.
Ackermann, B; Anderson, S; Ayan-Oshodi, M; Dean, R; Eckstein, J; Ho, M; Jackson, K; Lowe, S; McKinzie, D; Natanegara, F; Perry, K; Svensson, K; Yuen, E, 2012
)
0.38
" In contrast, mice dosed with the positive control substance, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP; 10mg/kg/dose×4 doses, 2 h apart), displayed significantly reduced DA and DOPAC concentrations and increased DA turnover in the striatum 7 days after dosing."( Pharmacokinetic, neurochemical, stereological and neuropathological studies on the potential effects of paraquat in the substantia nigra pars compacta and striatum of male C57BL/6J mice.
Beck, M; Botham, PA; Breckenridge, CB; Butt, M; Cook, AR; Mathews, JM; Minnema, D; Smith, LL; Sturgess, NC; Tisdel, MO; Travis, KZ; Wolf, JC; Zadory, D, 2013
)
0.39
" Behavioral deficits at the end of the 14-day dosing regime and on day 28 (i."( Intranasal administration of alpha-synuclein aggregates: a Parkinson's disease model with behavioral and neurochemical correlates.
Davydova, TV; Fomina, VG; Gruden, MA; Kudrin, VS; Morozova-Roche, LA; Narkevich, VB; Sewell, RD; Wang, C, 2014
)
0.4
"Following the intraperitoneal administration of silymarin (with MRP1, 2, 4 and 5 inhibitory effects), naringenin (with MRP1, 2 and 4 stimulatory effects), sulfinpyrazone (with MRP1, 4 and 5 inhibitory and MRP2 stimulatory effects) and allopurinol (with MRP4 stimulatory effect in doses of 100 mg/kg, 100 mg/kg, 100 mg/kg and 60 mg/kg, respectively, for one week before and after the administration of MPTP in C57B/6 mice in acute dosing regimen the striatal concentrations of dopamine, 3,4-dihydroxyphenylacetic acid and homovanillic acid has been measured using high-performance liquid chromatography."( Assessment of the role of multidrug resistance-associated proteins in MPTP neurotoxicity in mice.
Klivényi, P; Plangár, I; Szalárdy, L; Vécsei, L; Zádori, D, 2013
)
0.55
"5-year-old rhesus monkeys, n = 6) received single administration of doses of 1, 2, and 4 mg/kg day fluoxetine on a background of chronic dosing at an intermediate level to provide steady-state conditions to model therapeutic administration."( Fluoxetine: juvenile pharmacokinetics in a nonhuman primate model.
Golub, MS; Hogrefe, CE, 2014
)
0.4
" A dosage of 2 mg/kg day given over a 14-week period led to steady-state serum concentrations of active agent (fluoxetine + norfluoxetine) similar to those recorded from drug monitoring studies in children."( Fluoxetine: juvenile pharmacokinetics in a nonhuman primate model.
Golub, MS; Hogrefe, CE, 2014
)
0.4
" The 15% HT formulated extract did not induce micronuclei in rat bone marrow after 4 weeks of dosing up to 561 mg HT/kg/day."( Investigations into the genotoxic potential of olive extracts.
Beilstein, P; Edwards, J; Kirkland, D; Woehrle, T, 2015
)
0.42
" Male Sprague-Dawley (SD) rats were dosed orally with ACR at 0 (saline), 20, 30, and 40 mg/kg/day for 20 days."( Acrylamide increases dopamine levels by affecting dopamine transport and metabolism related genes in the striatal dopaminergic system.
Cheng, G; Guo, X; Lu, Q; Pan, X; Xiong, F; Yan, H, 2015
)
0.42
" Collectively, this data highlights the importance of the frontal cortex in methamphetamine-induced effects, and also the similar dose-response effect of methamphetamine on dopamine and BDNF expression."( Dose-Dependent Effects of Binge-Like Methamphetamine Dosing on Dopamine and Neurotrophin Levels in Rat Brain.
Doyle, KM; Kelly, JP; Moreira da Silva Santos, A, 2017
)
0.46
" Renal and biliary excretions and plasma concentration-time profiles of KYNA, pyridoxic acid (PDA), homovanillic acid (HVA), and coproporphyrin I (CP-I) were assessed in BDC monkeys dosed with either probenecid (PROB) at 100 mg/kg or the control vehicle."( Characterization of Elimination Pathways and the Feasibility of Endogenous Metabolites as Biomarkers of Organic Anion Transporter 1/3 Inhibition in Cynomolgus Monkeys.
Hao, J; Lai, Y; Liu, R; Zhao, X, 2023
)
1.13
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
human metaboliteAny mammalian metabolite produced during a metabolic reaction in humans (Homo sapiens).
mouse metaboliteAny mammalian metabolite produced during a metabolic reaction in a mouse (Mus musculus).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
monocarboxylic acidAn oxoacid containing a single carboxy group.
guaiacolsAny phenol carrying an additional methoxy substituent at the ortho-position.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (20)

PathwayProteinsCompounds
Neuronal System16650
Transmission across Chemical Synapses12250
Neurotransmitter clearance725
Clearance of dopamine413
Enzymatic degradation of dopamine by COMT310
Enzymatic degradation of Dopamine by monoamine oxidase210
Tyrosine Metabolism1657
Alkaptonuria1657
Hawkinsinuria1657
Tyrosinemia Type I1657
Disulfiram Action Pathway2366
Tyrosinemia, Transient, of the Newborn1657
Dopamine beta-Hydroxylase Deficiency1657
Monoamine Oxidase-A Deficiency (MAO-A)1657
Tyrosine metabolism ( Tyrosine metabolism )2841
NAD+ + 3-Methoxy-4-hydroxy-phenyl-acetaldehyde + H2O = NADH + Homovanillic acid ( Tyrosine metabolism )45
22q11.2 copy number variation syndrome228
Flavan-3-ol metabolic pathway070
Dopamine metabolism032
Neurotransmitter disorders819

Protein Targets (20)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, TYROSYL-DNA PHOSPHODIESTERASEHomo sapiens (human)Potency0.00890.004023.8416100.0000AID485290
thioredoxin reductaseRattus norvegicus (Norway rat)Potency42.28410.100020.879379.4328AID588453
ClpPBacillus subtilisPotency10.00001.995322.673039.8107AID651965
ATAD5 protein, partialHomo sapiens (human)Potency0.04610.004110.890331.5287AID493107
Fumarate hydrataseHomo sapiens (human)Potency5.62340.00308.794948.0869AID1347053
NFKB1 protein, partialHomo sapiens (human)Potency0.00350.02827.055915.8489AID895; AID928
GLS proteinHomo sapiens (human)Potency2.81840.35487.935539.8107AID624146
TDP1 proteinHomo sapiens (human)Potency6.51310.000811.382244.6684AID686978
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency25.11890.011212.4002100.0000AID1030
thyroid stimulating hormone receptorHomo sapiens (human)Potency3.16230.001318.074339.8107AID926
regulator of G-protein signaling 4Homo sapiens (human)Potency26.65410.531815.435837.6858AID504845
polyproteinZika virusPotency5.62340.00308.794948.0869AID1347053
arylsulfatase AHomo sapiens (human)Potency0.53581.069113.955137.9330AID720538
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency6.23030.035520.977089.1251AID504332
lysosomal alpha-glucosidase preproproteinHomo sapiens (human)Potency25.11890.036619.637650.1187AID2100
chromobox protein homolog 1Homo sapiens (human)Potency0.00600.006026.168889.1251AID488953
M-phase phosphoprotein 8Homo sapiens (human)Potency79.43280.177824.735279.4328AID488949
muscarinic acetylcholine receptor M1Rattus norvegicus (Norway rat)Potency0.01780.00106.000935.4813AID943
ATP-dependent phosphofructokinaseTrypanosoma brucei brucei TREU927Potency0.04780.060110.745337.9330AID485368
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Solute carrier family 22 member 8Rattus norvegicus (Norway rat)Km274.00000.73901.53952.3400AID681223
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (70)

Assay IDTitleYearJournalArticle
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347050Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347049Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID588378qHTS for Inhibitors of ATXN expression: Validation
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347405qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347410qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library2019Cellular signalling, 08, Volume: 60A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening.
AID1347151Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347059CD47-SIRPalpha protein protein interaction - Alpha assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID504836Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation2002The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16
Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588349qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay
AID1347057CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347058CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347045Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1268981Antiinflammatory activity in PMA-differentiated human U937 cells assessed as inhibition of LPS-stimulated TNF-alpha secretion at 125 uM preincubated for 2 hrs followed by LPS-stimulation measured after 24 hrs by ELISA relative to control2016Bioorganic & medicinal chemistry letters, Jan-15, Volume: 26, Issue:2
Anti-inflammatory properties of quebecol and its derivatives.
AID1268967Antiinflammatory activity in PMA-differentiated human U937 cells assessed as inhibition of LPS-stimulated IL-6 secretion at 500 uM preincubated for 2 hrs followed by LPS-stimulation measured after 24 hrs by ELISA relative to control2016Bioorganic & medicinal chemistry letters, Jan-15, Volume: 26, Issue:2
Anti-inflammatory properties of quebecol and its derivatives.
AID1268984Antiinflammatory activity in human U937-3xkB-luc cells assessed as inhibition of LPS-induced NFkappaB activation at 20 uM preincubated for 30 mins followed by LPS-stimulation measured after 6 hrs by luciferase assay relative to control2016Bioorganic & medicinal chemistry letters, Jan-15, Volume: 26, Issue:2
Anti-inflammatory properties of quebecol and its derivatives.
AID1268966Cytotoxicity against PMA-differentiated human U937 macrophages assessed as reduction in cell viability after 24 hrs by MTT assay2016Bioorganic & medicinal chemistry letters, Jan-15, Volume: 26, Issue:2
Anti-inflammatory properties of quebecol and its derivatives.
AID1268982Antiinflammatory activity in PMA-differentiated human U937 cells assessed as inhibition of LPS-stimulated TNF-alpha secretion at 62.5 uM preincubated for 2 hrs followed by LPS-stimulation measured after 24 hrs by ELISA relative to control2016Bioorganic & medicinal chemistry letters, Jan-15, Volume: 26, Issue:2
Anti-inflammatory properties of quebecol and its derivatives.
AID1268971Antiinflammatory activity in PMA-differentiated human U937 cells assessed as inhibition of LPS-stimulated IL-8 secretion at 500 uM preincubated for 2 hrs followed by LPS-stimulation measured after 24 hrs by ELISA relative to control2016Bioorganic & medicinal chemistry letters, Jan-15, Volume: 26, Issue:2
Anti-inflammatory properties of quebecol and its derivatives.
AID1268976Antiinflammatory activity in PMA-differentiated human U937 cells assessed as inhibition of LPS-stimulated IL-1beta secretion at 250 uM preincubated for 2 hrs followed by LPS-stimulation measured after 24 hrs by ELISA relative to control2016Bioorganic & medicinal chemistry letters, Jan-15, Volume: 26, Issue:2
Anti-inflammatory properties of quebecol and its derivatives.
AID338335Antiplatelet activity against rat platelet rich plasma assessed as inhibition of arachidonic acid-induced platelet aggregation at 0.25 mg/ml pretreated 2 mins before arachidonic acid challenge
AID681168TP_TRANSPORTER: uptake in Oat3-expressing oocyte cells2004The Journal of pharmacology and experimental therapeutics, Jun, Volume: 309, Issue:3
Mouse reduced in osteosclerosis transporter functions as an organic anion transporter 3 and is localized at abluminal membrane of blood-brain barrier.
AID1268974Antiinflammatory activity in PMA-differentiated human U937 cells assessed as inhibition of LPS-stimulated IL-8 secretion at 62.5 uM preincubated for 2 hrs followed by LPS-stimulation measured after 24 hrs by ELISA relative to control2016Bioorganic & medicinal chemistry letters, Jan-15, Volume: 26, Issue:2
Anti-inflammatory properties of quebecol and its derivatives.
AID1268973Antiinflammatory activity in PMA-differentiated human U937 cells assessed as inhibition of LPS-stimulated IL-8 secretion at 125 uM preincubated for 2 hrs followed by LPS-stimulation measured after 24 hrs by ELISA relative to control2016Bioorganic & medicinal chemistry letters, Jan-15, Volume: 26, Issue:2
Anti-inflammatory properties of quebecol and its derivatives.
AID1432860Anti-inflammatory activity in human U937-derived macrophage-like cells assessed as inhibition of LPS-induced IL-6 secretion at 250 uM preincubated for 2 hrs followed by LPS addition measured after 24 hrs by ELISA relative to control2017Bioorganic & medicinal chemistry, 04-01, Volume: 25, Issue:7
Synthesis and anti-inflammatory activity of isoquebecol.
AID681223TP_TRANSPORTER: uptake in Xenopus laevis oocytes2003Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism, Apr, Volume: 23, Issue:4
Rat organic anion transporter 3 (rOAT3) is responsible for brain-to-blood efflux of homovanillic acid at the abluminal membrane of brain capillary endothelial cells.
AID521220Inhibition of neurosphere proliferation of mouse neural precursor cells by MTT assay2007Nature chemical biology, May, Volume: 3, Issue:5
Chemical genetics reveals a complex functional ground state of neural stem cells.
AID1268978Antiinflammatory activity in PMA-differentiated human U937 cells assessed as inhibition of LPS-stimulated IL-1beta secretion at 62.5 uM preincubated for 2 hrs followed by LPS-stimulation measured after 24 hrs by ELISA relative to control2016Bioorganic & medicinal chemistry letters, Jan-15, Volume: 26, Issue:2
Anti-inflammatory properties of quebecol and its derivatives.
AID624612Specific activity of expressed human recombinant UGT1A92000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID1268972Antiinflammatory activity in PMA-differentiated human U937 cells assessed as inhibition of LPS-stimulated IL-8 secretion at 250 uM preincubated for 2 hrs followed by LPS-stimulation measured after 24 hrs by ELISA relative to control2016Bioorganic & medicinal chemistry letters, Jan-15, Volume: 26, Issue:2
Anti-inflammatory properties of quebecol and its derivatives.
AID1432864Anti-inflammatory activity in human U937-derived macrophage-like cells assessed as inhibition of LPS-induced IL-6 secretion at 500 uM preincubated for 2 hrs followed by LPS addition measured after 24 hrs by ELISA relative to control2017Bioorganic & medicinal chemistry, 04-01, Volume: 25, Issue:7
Synthesis and anti-inflammatory activity of isoquebecol.
AID1432863Anti-inflammatory activity in human U937-derived macrophage-like cells assessed as inhibition of LPS-induced IL-6 secretion at 31.25 uM preincubated for 2 hrs followed by LPS addition measured after 24 hrs by ELISA relative to control2017Bioorganic & medicinal chemistry, 04-01, Volume: 25, Issue:7
Synthesis and anti-inflammatory activity of isoquebecol.
AID1268983Antiinflammatory activity in human U937-3xkB-luc cells assessed as inhibition of LPS-induced NFkappaB activation at 100 uM preincubated for 30 mins followed by LPS-stimulation measured after 6 hrs by luciferase assay relative to control2016Bioorganic & medicinal chemistry letters, Jan-15, Volume: 26, Issue:2
Anti-inflammatory properties of quebecol and its derivatives.
AID1268979Antiinflammatory activity in PMA-differentiated human U937 cells assessed as inhibition of LPS-stimulated TNF-alpha secretion at 500 uM preincubated for 2 hrs followed by LPS-stimulation measured after 24 hrs by ELISA relative to control2016Bioorganic & medicinal chemistry letters, Jan-15, Volume: 26, Issue:2
Anti-inflammatory properties of quebecol and its derivatives.
AID1268970Antiinflammatory activity in PMA-differentiated human U937 cells assessed as inhibition of LPS-stimulated IL-6 secretion at 62.5 uM preincubated for 2 hrs followed by LPS-stimulation measured after 24 hrs by ELISA relative to control2016Bioorganic & medicinal chemistry letters, Jan-15, Volume: 26, Issue:2
Anti-inflammatory properties of quebecol and its derivatives.
AID681403TP_TRANSPORTER: inhibition of Indoxyl sulfate uptake (Indoxyl sulfate: 2 uM, HVA: 1000 uM) in Xenopus laevis oocytes2002Journal of neurochemistry, Oct, Volume: 83, Issue:1
Role of blood-brain barrier organic anion transporter 3 (OAT3) in the efflux of indoxyl sulfate, a uremic toxin: its involvement in neurotransmitter metabolite clearance from the brain.
AID1268985Antiinflammatory activity in human U937-3xkB-luc cells assessed as inhibition of LPS-induced NFkappaB activation at 5 uM preincubated for 30 mins followed by LPS-stimulation measured after 6 hrs by luciferase assay relative to control2016Bioorganic & medicinal chemistry letters, Jan-15, Volume: 26, Issue:2
Anti-inflammatory properties of quebecol and its derivatives.
AID624609Specific activity of expressed human recombinant UGT1A62000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID1453183Binding affinity to CK2alpha (unknown origin) assessed as change in melting temperature by thermal shift assay2017Bioorganic & medicinal chemistry, 07-01, Volume: 25, Issue:13
A fragment-based approach leading to the discovery of a novel binding site and the selective CK2 inhibitor CAM4066.
AID1268975Antiinflammatory activity in PMA-differentiated human U937 cells assessed as inhibition of LPS-stimulated IL-1beta secretion at 500 uM preincubated for 2 hrs followed by LPS-stimulation measured after 24 hrs by ELISA relative to control2016Bioorganic & medicinal chemistry letters, Jan-15, Volume: 26, Issue:2
Anti-inflammatory properties of quebecol and its derivatives.
AID338339Antiplatelet activity against rat platelet rich plasma assessed as inhibition of ADP-induced platelet aggregation at 1 mg/ml pretreated 2 mins before ADP challenge
AID524796Antiplasmodial activity against Plasmodium falciparum W2 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID682173TP_TRANSPORTER: inhibition of benzylpenicillin uptake by Homovanillic acid at a concentration of 1000uM in Oat3-expressing oocyte cells2004The Journal of pharmacology and experimental therapeutics, Jun, Volume: 309, Issue:3
Mouse reduced in osteosclerosis transporter functions as an organic anion transporter 3 and is localized at abluminal membrane of blood-brain barrier.
AID1268968Antiinflammatory activity in PMA-differentiated human U937 cells assessed as inhibition of LPS-stimulated IL-6 secretion at 250 uM preincubated for 2 hrs followed by LPS-stimulation measured after 24 hrs by ELISA relative to control2016Bioorganic & medicinal chemistry letters, Jan-15, Volume: 26, Issue:2
Anti-inflammatory properties of quebecol and its derivatives.
AID1432859Cytotoxicity against human U937-derived macrophage-like cells assessed as reduction in cell viability after 24 hrs by MTT assay2017Bioorganic & medicinal chemistry, 04-01, Volume: 25, Issue:7
Synthesis and anti-inflammatory activity of isoquebecol.
AID1432862Anti-inflammatory activity in human U937-derived macrophage-like cells assessed as inhibition of LPS-induced IL-6 secretion at 62.5 uM preincubated for 2 hrs followed by LPS addition measured after 24 hrs by ELISA relative to control2017Bioorganic & medicinal chemistry, 04-01, Volume: 25, Issue:7
Synthesis and anti-inflammatory activity of isoquebecol.
AID1268977Antiinflammatory activity in PMA-differentiated human U937 cells assessed as inhibition of LPS-stimulated IL-1beta secretion at 125 uM preincubated for 2 hrs followed by LPS-stimulation measured after 24 hrs by ELISA relative to control2016Bioorganic & medicinal chemistry letters, Jan-15, Volume: 26, Issue:2
Anti-inflammatory properties of quebecol and its derivatives.
AID1432861Anti-inflammatory activity in human U937-derived macrophage-like cells assessed as inhibition of LPS-induced IL-6 secretion at 125 uM preincubated for 2 hrs followed by LPS addition measured after 24 hrs by ELISA relative to control2017Bioorganic & medicinal chemistry, 04-01, Volume: 25, Issue:7
Synthesis and anti-inflammatory activity of isoquebecol.
AID1268969Antiinflammatory activity in PMA-differentiated human U937 cells assessed as inhibition of LPS-stimulated IL-6 secretion at 125 uM preincubated for 2 hrs followed by LPS-stimulation measured after 24 hrs by ELISA relative to control2016Bioorganic & medicinal chemistry letters, Jan-15, Volume: 26, Issue:2
Anti-inflammatory properties of quebecol and its derivatives.
AID1268980Antiinflammatory activity in PMA-differentiated human U937 cells assessed as inhibition of LPS-stimulated TNF-alpha secretion at 250 uM preincubated for 2 hrs followed by LPS-stimulation measured after 24 hrs by ELISA relative to control2016Bioorganic & medicinal chemistry letters, Jan-15, Volume: 26, Issue:2
Anti-inflammatory properties of quebecol and its derivatives.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5,840)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902735 (46.83)18.7374
1990's1750 (29.97)18.2507
2000's843 (14.43)29.6817
2010's441 (7.55)24.3611
2020's71 (1.22)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 75.65

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index75.65 (24.57)
Research Supply Index8.77 (2.92)
Research Growth Index4.24 (4.65)
Search Engine Demand Index138.91 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (75.65)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials312 (5.09%)5.53%
Reviews179 (2.92%)6.00%
Case Studies183 (2.99%)4.05%
Observational2 (0.03%)0.25%
Other5,451 (88.97%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]